122
Participants
Start Date
December 8, 2015
Primary Completion Date
February 28, 2017
Study Completion Date
September 26, 2017
Dolutegravir
Participants were prescribed 50 mg of DTG orally daily
Lamivudine
Participants were prescribed 300 mg of 3TC orally daily.
Cornell CRS (7804), New York
Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803), New York
Columbia Physicians and Surgeons CRS (30329), New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester
Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia
Greensboro CRS (3203), Greensboro
3201 Chapel Hill CRS, Chapel Hill
The Ponce de Leon Center CRS (5802), Atlanta
Univ. of Miami AIDS CRS (901), Miami
Vanderbilt Therapeutics CRS (3652), Nashville
The Ohio State Univ. AIDS CRS (2301), Columbus
Univ. of Cincinnati CRS (2401), Cincinnati
Northwestern University CRS (2701), Chicago
Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago
Washington University CRS (2101), St Louis
31443 Trinity Health and Wellness Center CRS, Dallas
Houston AIDS Research Team CRS (31473), Houston
University of Colorado Hospital CRS (6101), Aurora
University of Southern California CRS (1201), Los Angeles
UCLA CARE Center CRS (601), Los Angeles
Harbor-UCLA Med. Ctr. CRS (603), Torrance
Ucsd, Avrc Crs (701), San Diego
Massachusetts General Hospital ACTG CRS (101), Boston
Brigham and Women's Hosp. ACTG CRS (107), Boston
The Miriam Hospital ACTG CRS (2951), Providence
Puerto Rico-AIDS CRS (5401), San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK